Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart

British Journal of Pharmacology

Volumn 166, Issue 1, 2012, Pages 243-257

  Doan, N D ^a,b   Nguyen, T T M ^a,b   Letourneau M ^a,b   Turcotte, K ^a,b   Fournier, Alain ^a,b   Chatenet, D ^a,b  

^a INRS INSTITUT ARMAND FRAPPIER   (Canada)

^b International Associate Laboratory Samuel de Champlain   (Canada)

Author keywords

cardiovascular; endocytosis; intracrine; nuclear receptors; urotensin II related peptide; urotensin II

Indexed keywords

CAVEOLIN; FLUORESCEIN; UROTENSIN RECEPTOR;

ANIMAL TISSUE; ARTICLE; BINDING ASSAY; BINDING SITE; CELL PH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOCYTOSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HEART MUSCLE FIBER MEMBRANE; IMMUNOBLOTTING; IN VITRO STUDY; INTRACELLULAR SPACE; ISOLATED HEART; MALE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RAT; RECEPTOR BINDING; RNA SYNTHESIS; TRANSCRIPTION INITIATION;

ANIMALS; BINDING SITES; CELL MEMBRANE; CELL NUCLEUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MACACA FASCICULARIS; MALE; MYOCARDIUM; PEPTIDE HORMONES; PHOTOAFFINITY LABELS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS;

EID: 84856091972     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01710.x     Document Type: Article

References (49)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al,. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
2. Andreev OA, Karabadzhak AG, Weerakkody D, Andreev GO, Engelman DM, Reshetnyak YK, (2010). pH (low) insertion peptide (pHLIP) inserts across a lipid bilayer as a helix and exits by a different path. Proc Natl Acad Sci U S A 107: 4081-4086.
3. Boivin B, Chevalier D, Villeneuve LR, Rousseau E, Allen BG, (2003). Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 278: 29153-29163.
4. Boivin B, Lavoie C, Vaniotis G, Baragli A, Villeneuve LR, Ethier N, et al,. (2006). Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes. Cardiovasc Res 71: 69-78.
5. Boivin B, Vaniotis G, Allen BG, Hebert TE, (2008). G protein-coupled receptors in and on the cell nucleus: a new signaling paradigm? J Recept Signal Transduct Res 28: 15-28.
6. Bootman MD, Fearnley C, Smyrnias I, MacDonald F, Roderick HL, (2009). An update on nuclear calcium signalling. J Cell Sci 122 (Pt 14): 2337-2350.
7. Brkovic A, Hattenberger A, Kostenis E, Klabunde T, Flohr S, Kurz M, et al,. (2003). Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J Pharmacol Exp Ther 306: 1200-1209.
8. Castel H, Diallo M, Chatenet D, Leprince J, Desrues L, Schouft MT, et al,. (2006). Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 99: 582-595.
9. Chatenet D, Dubessy C, Leprince J, Boularan C, Carlier L, Segalas-Milazzo I, et al,. (2004). Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25: 1819-1830.
10. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al,. (1998). Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 95: 15803-15808.
11. Crampin EJ, Smith NP, Langham AE, Clayton RH, Orchard CH, (2006). Acidosis in models of cardiac ventricular myocytes. Philos Transact A Math Phys Eng Sci 364: 1171-1186.
12. De Mello WC, (2008). Intracellular and extracellular renin have opposite effects on the regulation of heart cell volume. Implications for myocardial ischaemia. J Renin Angiotensin Aldosterone Syst 9: 112-118.
13. Dennison SR, Baker RD, Nicholl ID, Phoenix DA, (2007). Interactions of cell penetrating peptide Tat with model membranes: a biophysical study. Biochem Biophys Res Commun 363: 178-182.
14. Doan ND, Bourgault S, Dejda A, Letourneau M, Detheux M, Vaudry D, et al,. (2011). Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Biochem Pharmacol 81: 552-561.
15. Dolmetsch RE, Xu K, Lewis RS, (1998). Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392: 933-936.
16. Douglas SA, Ohlstein EH, (2000). Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10: 229-237.
17. Du AT, Onan D, Dinh DT, Lew MJ, Ziogas J, Aguilar MI, et al,. (2010). Ligand-supported purification of the urotensin-II receptor. Mol Pharmacol 78: 639-647.
18. Dubessy C, Cartier D, Lectez B, Bucharles C, Chartrel N, Montero-Hadjadje M, et al,. (2008). Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. J Neurochem 107: 361-374.
19. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, et al,. (2002). Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136: 9-22.
20. Erchegyi J, Hoeger CA, Low W, Hoyer D, Waser B, Eltschinger V, et al,. (2005). Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem 48: 507-514.
21. Ferone D, Boschetti M, Resmini E, Giusti M, Albanese V, Goglia U, et al,. (2006). Neuroendocrine-immune interactions: the role of cortistatin/ somatostatin system. Ann N Y Acad Sci 1069: 129-144.
22. Giebing G, Tolle M, Jurgensen J, Eichhorst J, Furkert J, Beyermann M, et al,. (2005). Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin II-mediated vasoconstriction. Circ Res 97: 707-715.
23. Gong H, Wang YX, Zhu YZ, Wang WW, Wang MJ, Yao T, et al,. (2004). Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. J Appl Physiol 97: 2228-2235.
24. Guidolin D, Albertin G, Oselladore B, Sorato E, Rebuffat P, Mascarin A, et al,. (2010). The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways. Regul Pept 162: 26-32.
25. Holm T, Johansson H, Lundberg P, Pooga M, Lindgren M, Langel U, (2006). Studying the uptake of cell-penetrating peptides. Nat Protoc 1: 1001-1005.
26. Jarry M, Diallo M, Lecointre C, Desrues L, Tokay T, Chatenet D, et al,. (2010). The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. Biochem J 428: 113-124.
27. Jong YJ, Kumar V, O'Malley KL, (2009). Intracellular metabotropic glutamate receptor 5 (mGluR5) activates signaling cascades distinct from cell surface counterparts. J Biol Chem 284: 35827-35838.
28. Jullian M, Hernandez A, Maurras A, Puget K, Amblard M, Martinez J, et al,. (2009). N-terminus FITC labeling of peptides on solid support: the truth behind the spacer. Tetrahedron Lett 50: 260-263.
29. Lavecchia A, Cosconati S, Novellino E, (2005). Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists. J Med Chem 48: 2480-2492.
30. Leprince J, Chatenet D, Dubessy C, Fournier A, Pfeiffer B, Scalbert E, et al,. (2008). Structure-activity relationships of urotensin II and URP. Peptides 29: 658-673.
31. Maryanoff BE, Kinney WA, (2010). Urotensin-II receptor modulators as potential drugs. J Med Chem 53: 2695-2708.
32. Nakayama T, Hirose T, Totsune K, Mori N, Maruyama Y, Maejima T, et al,. (2008). Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides 29: 801-808.
33. Patel CB, Noor N, Rockman HA, (2010). Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol 78: 983-992.
34. Petersen MC, Munzenmaier DH, Greene AS, (2006). Angiotensin II infusion restores stimulated angiogenesis in the skeletal muscle of rats on a high-salt diet. Am J Physiol Heart Circ Physiol 291: H114-H120.
35. Prosser HC, Forster ME, Richards AM, Pemberton CJ, (2008). Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury. Peptides 29: 770-777.
36. Proulx CD, Holleran BJ, Lavigne P, Escher E, Guillemette G, Leduc R, (2008). Biological properties and functional determinants of the urotensin II receptor. Peptides 29: 691-699.
37. Ross B, McKendy K, Giaid A, (2010). Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 298: R1156-R1172.
38. Russell FD, (2008). Urotensin II in cardiovascular regulation. Vasc Health Risk Manag 4: 775-785.
39. Segain JP, Rolli-Derkinderen M, Gervois N, Raingeard de la Bletiere D, Loirand G, Pacaud P, (2007). Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179: 901-909.
40. Singh VP, Le B, Bhat VB, Baker KM, Kumar R, (2007). High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 293: H939-H948.
41. Sugo T, Mori M, (2008). Another ligand fishing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain. Peptides 29: 809-812.
42. Tadevosyan A, Maguy A, Villeneuve LR, Babin J, Bonnefoy A, Allen BG, et al,. (2010). Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem 285: 22338-22349.
43. Tominaga A, Sugawara H, Futagawa T, Inoue K, Sasaki K, Minamino N, et al,. (2010). Characterization of the testis-specific promoter region in the human pituitary adenylate cyclase-activating polypeptide (PACAP) gene. Genes Cells 15: 595-606.
44. Tostivint H, Lihrmann I, Vaudry H, (2008). New insight into the molecular evolution of the somatostatin family. Mol Cell Endocrinol 286: 5-17.
45. Vaniotis G, Del Duca D, Trieu P, Rohlicek CV, Hebert TE, Allen BG, (2011). Nuclear beta-adrenergic receptors modulate gene expression in adult rat heart. Cell Signal 23: 89-98.
46. Vaudry H, Do Rego JC, Le Mevel JC, Chatenet D, Tostivint H, Fournier A, et al,. (2010). Urotensin II, from fish to human. Ann N Y Acad Sci 1200: 53-66.
47. Vergura R, Camarda V, Rizzi A, Spagnol M, Guerrini R, Calo G, et al,. (2004). Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn Schmiedebergs Arch Pharmacol 370: 347-352.
48. Ye K, Ahn JY, (2008). Nuclear phosphoinositide signaling. Front Biosci 13: 540-548.
49. Zaro JL, Vekich JE, Tran T, Shen WC, (2009). Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells. Mol Pharm 6: 337-344.